KCM
TPST icon

Kennedy Capital Management’s Tempest Therapeutics TPST Stock Holding History

Kennedy Capital Management’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-146
Closed -$3.91M – 782
2014
Q2 		$3.91M Sell
146
-9
-6% -$212K 0.07% 430
2014
Q1 		$4.04M Buy
155
+135
+675% +$3.83M 0.08% 413
2013
Q4 		$538K Buy
+20
New +$548K 0.01% 692

Other funds holding TPST

DVC
Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
BCM
BBT Capital Management Fort Worth, Texas $85.5M AUM 11.09% 1-Year Est. Return
TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Kennedy Capital Management's TPST Position: Q3 2014 in Review

Kennedy Capital Management sold out of Tempest Therapeutics (TPST) in Q3 2014, closing a stake of 146 shares — an estimated $3.91M sold.

Kennedy Capital Management first reported a position in TPST in Q4 2013 and held it in 3 quarters. The position peaked at $4.04M in Q1 2014. 53 funds tracked by Wall St. Rank hold TPST as of Q3 2014.

  • Kennedy Capital Management reported no remaining Tempest Therapeutics position as of Q3 2014 after selling out during the quarter.
  • Kennedy Capital Management sold 146 Tempest Therapeutics shares in Q3 2014, an estimated $3.91M.
  • Kennedy Capital Management first reported a position in Tempest Therapeutics in Q4 2013 and held it in 3 quarters.
  • Kennedy Capital Management's Tempest Therapeutics position peaked at $4.04M in Q1 2014.
  • 53 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q3 2014.

Based on Kennedy Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.